NextCure, Inc. (NASDAQ:NXTC) Sees Significant Decline in Short Interest

Posted by George Bondi on Aug 12th, 2026

NextCure, Inc. (NASDAQ:NXTC – Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 141,248 shares, a decline of 89.3% from the July 15th total of 1,323,834 shares. Based on an average trading volume of 862,182 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.4% of the company’s shares are sold short.

NextCure Stock Performance

NASDAQ NXTC traded up $1.18 during trading hours on Wednesday, reaching $7.91. The stock had a trading volume of 328,448 shares, compared to its average volume of 910,181. NextCure has a 52-week low of $1.55 and a 52-week high of $15.74. The stock has a fifty day moving average of $3.49 and a 200 day moving average of $8.29. The stock has a market cap of $28.57 million, a P/E ratio of -0.91 and a beta of 1.27.

NextCure (NASDAQ:NXTC – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85). On average, equities research analysts forecast that NextCure will post -7.99 EPS for the current year.

Wall Street Analyst Weigh In

NXTC has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Finally, Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.00.

View Our Latest Analysis on NextCure

Insider Transactions at NextCure

In related news, major shareholder Adar1 Capital Management, Llc acquired 292,850 shares of the stock in a transaction on Thursday, July 30th. The stock was bought at an average cost of $4.93 per share, with a total value of $1,443,750.50. Following the transaction, the insider directly owned 686,116 shares in the company, valued at approximately $3,382,551.88. This represents a 74.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders acquired 346,761 shares of company stock worth $1,710,807. 11.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Ikarian Capital LLC acquired a new stake in shares of NextCure in the 4th quarter worth $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure during the 4th quarter worth $3,363,000. Boothbay Fund Management LLC acquired a new position in shares of NextCure during the 4th quarter valued at about $988,000. Affinity Asset Advisors LLC boosted its position in shares of NextCure by 28.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after acquiring an additional 55,412 shares during the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in shares of NextCure in the fourth quarter valued at about $1,665,000. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

(Get Free Report)

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.